Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Next Previous
Trial Profile

A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVB 101 (Primary)
  • Indications Frontotemporal dementia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ASPIRE-FTD; FTD-GRN
  • Sponsors AviadoBio

Most Recent Events

  • 21 Jan 2026 Planned End Date changed from 31 Oct 2030 to 21 Mar 2030.
  • 15 May 2025 According to an AviadoBios media release, patient enrollment is now open in the UK's Cambridge University Hospitals NHS Foundation Trust (CUH) and University College London (UCL) is also expected to open for patient recruitment shortly.
  • 01 May 2025 According to an AviadoBios media release, the company intends to initiate dosing for a third cohort in Q3 2025 and biomarker data readout is expected in 2026. Additional countries are expected to join the trial in the near future.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top